NEURALPLEXER Trademark
NEURALPLEXER is a USPTO trademark filed by Iambic Therapeutics, Inc.. Status: Pending.
Trademark Facts
| Mark | NEURALPLEXER |
|---|---|
| Serial Number | 99014025 |
| Status | Pending |
| Filing Date | 2025-01-21 |
| Mark Type | Word |
| Nice Classes | 042 (Software & IT) |
| Owner | Iambic Therapeutics, Inc. |
| Attorney of Record | Alyssa M. Worsham |
| Prosecution Events | 14 |
| Latest Event | EISU on 2026-04-07 |
Goods & Services
Drug discovery services; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence and machine learning for molecular docking; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence for biomolecular structure prediction; platform as a service (PAAS) featuring a computer software platform for using artificial intelligence in the field of drug design and development; research and development of new therapeutic targets for others; scientific and medical research; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for collecting, analyzing, interpreting and reporting data and information in the field of drug design and development; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for molecular docking; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for biomolecular structure prediction; artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for automated machine learning in the field of drug design and development; advanced product research in the field of artificial intelligence (AI); research and development of pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; medical and scientific research services in the field of machine learning models for biomolecular structure prediction